Replies to post #177777 on Biotech Values

[zipjet]

ITMN is my biggest risk investment (all biotechs fit that).

Own FURX and will hold for the CVR.

GILD for a few days was my biggest, sold most of for a nice STCG. Glad to see them buying stock but do not know the pipeline well enough to hold it for long. I follow the HCV-cliff theory. :-)

A few days back I bought PCYC on the selloff and yesterday bought NPSP. The bounce in NPSP stunned me.

[ghmm]

Not surprising I am long a couple of your picks (ITMN, ENTA) and like/watch some of the others (PRTA and RARE). Even though I like RARE I am a bit surprised you picked it up now. I realize you take a long term view (so do I) I just see the valuation as still quite high given they are basically still phase 2 assets. I certainly could see them never reaching what I would see as a fair valuation (probably in the mid 20's) or my buy range (upper teens - low 20's). Is there a program in particular you like?

[DewDiligence]

FMI update re European business:

http://finance.yahoo.com/news/foundation-medicine-announces-key-developments-103000953.html

Foundation Medicine, Inc. (FMI) today announced that it has obtained a CE mark for FoundationOne. The CE mark allows FoundationOne to be placed on the market in the European Economic Area. In addition, Foundation Medicine has added to its growing global business partners by establishing a partnership with Barcelona, Spain-based Laboratorios LETI for the distribution of the company’s clinical products to physicians in Spain and Portugal. The company anticipates this partnership will serve as a model for similar commercial relationships with leading distributors in select markets around the world.